Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Changhui LiWei NieJingdong GuoAnning XiongHua ZhongTianqing ChuRunbo ZhongJianlin XuJun LuXiaoxuan ZhengBo ZhangYinchen ShenFeng PanBaohui HanXueyan ZhangPublished in: Respiratory research (2021)
In advanced patients with an acquired EGFR T790M mutation after obtaining first-generation EGFR-TKI resistance, osimertinib may be more limited in its control in BM than in non-BM. Also, osimertinib combined with brain radiotherapy may improve the survival time of BM patients.
Keyphrases
- small cell lung cancer
- brain metastases
- epidermal growth factor receptor
- advanced non small cell lung cancer
- tyrosine kinase
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- early stage
- prognostic factors
- radiation therapy
- peritoneal dialysis
- multiple sclerosis
- patient reported
- blood brain barrier
- cerebral ischemia
- functional connectivity